Leaflet DOXORUBICINA ACCORD 2mg / ml concentrate for solution for infusion


Indicated for: cancer

Substance: doxorubicin (antineoplastic agent)

ATC: L01DB01 (Antineoplastic and immunomodulating agents | Cytotoxic antibiotics and related substances | Anthracyclines and related substances)

Doxorubicinum is a chemotherapy drug used for the treatment of various types of cancer, including breast cancer, leukemia, and lymphoma. It belongs to the anthracycline class and works by inhibiting DNA synthesis in cancer cells, preventing their division and growth.

The medication is administered intravenously, usually as part of a specific regimen, under the supervision of an oncologist. It is effective in reducing tumor size and slowing disease progression.

Side effects may include nausea, vomiting, hair loss, bone marrow suppression, and, in rare cases, cardiac toxicity. Close monitoring is essential during treatment.

Consult your doctor to discuss the benefits and risks of treatment with Doxorubicinum. This medication must be administered exclusively in controlled environments, such as hospitals.

General data about DOXORUBICINA ACCORD 2mg / ml

  • Substance: doxorubicin
  • Date of last drug list: 01-05-2026
  • Commercial code: W65789004
  • Concentration: 2mg / ml
  • Pharmaceutical form: concentrate for solution for infusion
  • Quantity: 1
  • Product type: generic
  • Price: 42.76 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: ACCORD HEALTHCARE LIMITED - MAREA BRITANIE
  • Holder: ACCORD HEALTHCARE POLSKA SP. Z O.O. - POLONIA
  • Number: 10647/2018/02
  • Shelf life: 18 months-after packing for marketing;after the first opening of the bottle-it is used immediately

Concentrations available for doxorubicin

  • 10mg
  • 2mg/ml
  • 50mg

Compensation lists for DOXORUBICINA ACCORD 2mg / ml Accord

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

42.76 RON

42.76 RON

0.00 RON